Multiple Myeloma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Multiple Myeloma Emerging Therapy and TPP Insights

Thelansis’s “Multiple Myeloma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Multiple Myeloma Overview

Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow, which secrete significant quantities of non-functional proteins and immunoglobulins. Despite notable therapeutic advancements over many years, MM remains largely incurable. These hyperproliferative differentiated B-lymphocytes can produce various types of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, these abnormal plasma cells primarily grow within the bone marrow, with only a small fraction of patients initially showing extramedullary disease. Most patients experience relapses during treatment, progress to a refractory state, and cease to respond to therapy within 60 days of their last treatment: a grim prognosis and a high likelihood of relapse mark this. Additionally, with each subsequent relapse, patients endure progressively shorter periods of progression-free survival (PFS). For instance, PFS for first-line patients is around 18 months, but by the fourth line of therapy, it dwindles to a mere 4.7 months.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)